JP2017507919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507919A5 JP2017507919A5 JP2016546921A JP2016546921A JP2017507919A5 JP 2017507919 A5 JP2017507919 A5 JP 2017507919A5 JP 2016546921 A JP2016546921 A JP 2016546921A JP 2016546921 A JP2016546921 A JP 2016546921A JP 2017507919 A5 JP2017507919 A5 JP 2017507919A5
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- antigen
- region
- amino acid
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 210000002865 immune cell Anatomy 0.000 claims 11
- 238000006467 substitution reaction Methods 0.000 claims 11
- 108060003951 Immunoglobulin Proteins 0.000 claims 10
- 102000018358 immunoglobulin Human genes 0.000 claims 10
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 8
- 108010087819 Fc receptors Proteins 0.000 claims 8
- 102000009109 Fc receptors Human genes 0.000 claims 8
- 230000035772 mutation Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 230000004068 intracellular signaling Effects 0.000 claims 7
- 108700012439 CA9 Proteins 0.000 claims 6
- 102100023123 Mucin-16 Human genes 0.000 claims 6
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 4
- 108010008629 CA-125 Antigen Proteins 0.000 claims 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 4
- 108010009685 Cholinergic Receptors Proteins 0.000 claims 4
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 4
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 4
- 102100034256 Mucin-1 Human genes 0.000 claims 4
- 108010008707 Mucin-1 Proteins 0.000 claims 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 4
- 101710120463 Prostate stem cell antigen Proteins 0.000 claims 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 4
- 102000034337 acetylcholine receptors Human genes 0.000 claims 4
- 150000002270 gangliosides Chemical class 0.000 claims 4
- 125000006850 spacer group Chemical group 0.000 claims 4
- 102100021852 Neuronal cell adhesion molecule Human genes 0.000 claims 3
- 101710130688 Neuronal cell adhesion molecule Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001605 fetal effect Effects 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- -1 CD44v7 / 8 Proteins 0.000 claims 2
- 108010065524 CD52 Antigen Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 2
- 101000904196 Homo sapiens Pancreatic secretory granule membrane major glycoprotein GP2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 2
- 102100024019 Pancreatic secretory granule membrane major glycoprotein GP2 Human genes 0.000 claims 2
- 108010006700 Receptor Tyrosine Kinase-like Orphan Receptors Proteins 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 101800000385 Transmembrane protein Proteins 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 2
- 102000003425 Tyrosinase Human genes 0.000 claims 2
- 108060008724 Tyrosinase Proteins 0.000 claims 2
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 2
- SRHNADOZAAWYLV-XLMUYGLTSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O SRHNADOZAAWYLV-XLMUYGLTSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 101150058049 car gene Proteins 0.000 claims 2
- 230000004940 costimulation Effects 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 1
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461926881P | 2014-01-13 | 2014-01-13 | |
| US61/926,881 | 2014-01-13 | ||
| PCT/US2014/028961 WO2015105522A1 (en) | 2014-01-13 | 2014-03-14 | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017507919A JP2017507919A (ja) | 2017-03-23 |
| JP2017507919A5 true JP2017507919A5 (enExample) | 2017-04-27 |
| JP6560235B2 JP6560235B2 (ja) | 2019-08-14 |
Family
ID=53524229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016546921A Active JP6560235B2 (ja) | 2014-01-13 | 2014-03-14 | Ｆｃスペーサー領域に変異を有するキメラ抗原受容体（ＣＡＲ）及びそれらの使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20160333108A1 (enExample) |
| EP (2) | EP3094653B1 (enExample) |
| JP (1) | JP6560235B2 (enExample) |
| CN (2) | CN107074957B (enExample) |
| AU (3) | AU2014376328A1 (enExample) |
| ES (1) | ES2767423T3 (enExample) |
| WO (1) | WO2015105522A1 (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2949648T3 (es) | 2012-12-20 | 2023-10-02 | Purdue Research Foundation | Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| WO2015105522A1 (en) | 2014-01-13 | 2015-07-16 | Forman Stephen J | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| JP6788573B6 (ja) | 2014-04-10 | 2020-12-16 | シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート | メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造 |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| PL3183268T3 (pl) | 2014-08-19 | 2020-09-07 | Novartis Ag | Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego |
| AU2015317351B2 (en) * | 2014-09-19 | 2020-07-02 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| MX2017013471A (es) * | 2015-04-27 | 2018-08-01 | Abvitro Llc | Metodo de secuenciamiento, determinacion, apareamiento y validacion de agentes terapeuticos y antigenos especificos de enfermedades. |
| EP3288570A4 (en) | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| EP3294764B1 (en) | 2015-05-15 | 2020-12-30 | City of Hope | Chimeric antigen receptor compositions |
| CA2994829A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| ES2911015T3 (es) | 2015-08-31 | 2022-05-17 | Helixmith Co Ltd | Receptores quiméricos de antígeno anti-sialil Tn |
| AU2016336515B2 (en) * | 2015-10-06 | 2023-08-24 | City Of Hope | Chimeric antigen receptors targeted to PSCA |
| KR20180056780A (ko) | 2015-10-13 | 2018-05-29 | 시티 오브 호프 | 클로로톡신 도메인을 함유하는 키메라 항원 수용체 |
| EP3368075B1 (en) * | 2015-10-27 | 2020-01-29 | Board of Regents, The University of Texas System | Chimeric antigen receptor molecules and uses thereof |
| RU2753695C2 (ru) * | 2015-11-04 | 2021-08-19 | Сол Дж. ПРАЙСМЕН | Химерные рецепторы антигена, нацеленные на her2 |
| ES2879700T3 (es) * | 2016-02-05 | 2021-11-22 | Hope City | Administración de células T genomanipuladas para el tratamiento de cánceres en el sistema nervioso central |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| WO2017177149A2 (en) | 2016-04-08 | 2017-10-12 | Purdue Research Foundation | Methods and compositions for car t cell therapy |
| IL321834A (en) * | 2016-06-08 | 2025-08-01 | Precigen Inc | Cd33 specific chimeric antigen receptors |
| CN106117366A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种cd19特异性嵌合抗原受体及其编码基因、应用 |
| JP6896057B2 (ja) | 2016-07-12 | 2021-06-30 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | 抗原結合分子及びその使用方法 |
| WO2018042385A2 (en) | 2016-09-02 | 2018-03-08 | The Regents Of The University Of California | Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments |
| EP3518944A4 (en) * | 2016-09-30 | 2020-06-17 | Baylor College of Medicine | ADAPTIVE CHIMERIC ANTIGENT RECEPTOR T-CELL DESIGN |
| US11116834B2 (en) | 2016-10-19 | 2021-09-14 | City Of Hope | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy |
| AU2017375630B2 (en) | 2016-12-12 | 2023-12-21 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
| CN108395482B (zh) | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
| KR20240139092A (ko) * | 2017-05-01 | 2024-09-20 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 요법 및 면역조절 화합물의 조합 |
| EP3679072A1 (en) * | 2017-09-06 | 2020-07-15 | Fred Hutchinson Cancer Research Center | Strep-tag specific chimeric receptors and uses thereof |
| EP3684803A1 (en) | 2017-09-22 | 2020-07-29 | Kite Pharma, Inc. | Antigen binding molecules and methods of use thereof |
| US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| EP3707246B1 (en) * | 2017-11-07 | 2023-06-07 | City of Hope | Treatment of cns lymphoma and systemic lymphoma with intracerebroventricularly administered cd19 car |
| CN109971712B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途 |
| CN109971723B (zh) * | 2017-12-28 | 2023-07-07 | 上海细胞治疗研究院 | 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途 |
| CN109971722B (zh) * | 2017-12-28 | 2023-09-01 | 上海细胞治疗研究院 | 靶向cd19且高水平稳定表达cd40抗体的car-t细胞及其用途 |
| CN109971716B (zh) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| CN109971721B (zh) * | 2017-12-28 | 2023-10-31 | 上海细胞治疗研究院 | 自表达cd47抗体的间皮素特异性car-t细胞及其用途 |
| CN109971717B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途 |
| CN109971725B (zh) | 2017-12-28 | 2024-02-02 | 上海细胞治疗研究院 | 抗体修饰的嵌合抗原受体修饰t细胞及其用途 |
| CN109971714B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 自表达pd-1抗体并靶向间皮素的嵌合抗原受体修饰t细胞及其用途 |
| TW201940182A (zh) | 2018-01-22 | 2019-10-16 | 美商安德賽特公司 | Car t 細胞之使用方法 |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| US20210079061A1 (en) * | 2018-02-26 | 2021-03-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| CN112566643A (zh) * | 2018-06-12 | 2021-03-26 | 加利福尼亚大学董事会 | 用于治疗癌症的单链双特异性嵌合抗原受体 |
| BR112021000914A2 (pt) * | 2018-07-18 | 2021-04-13 | Amgen Inc. | Receptores quiméricos para steap1 e seus métodos de uso |
| AU2019330347B2 (en) | 2018-08-29 | 2025-07-24 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| AU2019337603A1 (en) * | 2018-09-13 | 2021-05-13 | Nkarta, Inc. | Natural killer cell compositions and immunotherapy methods for treating tumors |
| CN109096405B (zh) * | 2018-09-20 | 2021-07-09 | 杭州普略生物科技有限公司 | 以gd2为靶点的嵌合抗原受体及药物组合物 |
| EP3861854B1 (en) * | 2018-09-27 | 2025-01-22 | Central Institute for Experimental Medicine and Life Science | Immunodeficient mouse |
| BR112021008289A2 (pt) | 2018-11-01 | 2021-10-26 | Juno Therapeutics, Inc. | Métodos para tratamento utilizando receptores de antígeno quimérico específico para antígeno de maturação de célula b |
| BR112021008930A2 (pt) | 2018-11-08 | 2021-11-03 | Juno Therapeutics Inc | Métodos e combinações para o tratamento e modulação de célula t |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| CN118184800A (zh) * | 2019-05-07 | 2024-06-14 | 亘喜生物科技（上海）有限公司 | 靶向bcma的工程化免疫细胞及其用途 |
| EP3964238A4 (en) * | 2019-05-07 | 2022-09-14 | Gracell Biotechnologies (Shanghai) Co., Ltd. | MODIFIED IMMUNE CELL TARGETTING BCMA AND ITS USE |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| CN111499763A (zh) * | 2020-03-31 | 2020-08-07 | 江苏省省级机关医院 | 一种靶向mage-a1的特异性全人源嵌合抗原受体及其应用 |
| KR20230004680A (ko) * | 2020-04-17 | 2023-01-06 | 시티 오브 호프 | Flt3-양성 악성 종양의 치료를 위한 flt3-표적화된 키메라 항원 수용체 변형 세포 |
| CN115461361B (zh) * | 2020-05-08 | 2025-03-14 | 玛希敦大学 | 嵌合抗原受体和携带该受体的经修饰的细胞 |
| BR112022022953A2 (pt) * | 2020-05-12 | 2023-03-21 | Lyell Immunopharma Inc | Espaçadores de receptores de antígenos quiméricos |
| EP4210831A2 (en) | 2020-09-10 | 2023-07-19 | Mustang Bio, Inc. | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer |
| CN112111014A (zh) * | 2020-09-22 | 2020-12-22 | 廖文强 | 一种抗氧化嵌合型抗原受体和免疫细胞 |
| WO2022105811A1 (zh) * | 2020-11-20 | 2022-05-27 | 江苏先声药业有限公司 | Cd19人源化抗体及其应用 |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021402100A1 (en) * | 2020-12-16 | 2023-07-27 | Orion Corporation | Chimeric antigen receptor (car) spacer modifications enhance car t cell functionality |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CN115873126A (zh) * | 2021-11-26 | 2023-03-31 | 深圳科兴药业有限公司 | 人生长激素融合蛋白及其制备和用途 |
| CN117004604A (zh) * | 2022-04-28 | 2023-11-07 | 南京北恒生物科技有限公司 | 一种ciita基因被敲除的工程化免疫细胞及其用途 |
| CN119923410A (zh) | 2022-07-28 | 2025-05-02 | 莱蒂恩技术公司 | 用于治疗实体瘤的嵌合抗原受体治疗 |
| CN116254230A (zh) * | 2022-09-14 | 2023-06-13 | 卡瑞济(北京)生命科技有限公司 | 用于制备和扩增通用型人源化抗cd19 car-nk细胞的方法及其用途 |
| CN117942275A (zh) * | 2022-10-31 | 2024-04-30 | 康码（上海）生物科技有限公司 | 一种基于病毒阻断剂的洗手液及其应用 |
| WO2024118866A1 (en) | 2022-12-01 | 2024-06-06 | Modernatx, Inc. | Gpc3-specific antibodies, binding domains, and related proteins and uses thereof |
| EP4626447A1 (en) | 2023-03-31 | 2025-10-08 | AbelZeta Inc. | Bispecific chimeric antigen receptors targeting cd20 and bcma |
| CN119101166A (zh) * | 2023-06-08 | 2024-12-10 | 博生吉医药科技(苏州)有限公司 | B7-H3嵌合抗原受体修饰的Vδ1 T细胞及其应用 |
| WO2025064828A1 (en) * | 2023-09-20 | 2025-03-27 | Kure.Ai, Inc. | Methods and reagents to improve cell therapy with the creation of novel car-targeting mr1 protein |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8414892B2 (en) * | 2000-10-18 | 2013-04-09 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US20020102264A1 (en) * | 2000-10-18 | 2002-08-01 | Cheung Nai-Kong V. | Uses of monoclonal antibody 8H9 |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| MXPA06008746A (es) | 2004-02-06 | 2007-01-23 | Elan Pharm Inc | Metodos y composiciones para tratamiento de tumores y enfermedad metastatica. |
| US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
| SI2250279T1 (sl) * | 2008-02-08 | 2016-10-28 | Medimmune, Llc | Protitelesa anti-IFNAR1 z zmanjšano afiniteto do FC liganda |
| US8822647B2 (en) | 2008-08-26 | 2014-09-02 | City Of Hope | Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells |
| EP2389192A4 (en) | 2009-01-23 | 2013-01-16 | Biogen Idec Inc | STABILIZED FC POLYPEPTIDES WITH REDUCED EFFECTOR FUNCTION AND METHOD OF USE |
| SI2496698T1 (sl) | 2009-11-03 | 2019-07-31 | City Of Hope | Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic |
| EP2614077B1 (en) * | 2010-09-08 | 2016-08-17 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| DK2718322T3 (en) * | 2011-06-06 | 2018-12-03 | Novo Nordisk As | THERAPEUTIC ANTIBODIES |
| AU2013221672B2 (en) * | 2012-02-13 | 2017-11-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US10040846B2 (en) | 2012-02-22 | 2018-08-07 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer |
| US9573988B2 (en) | 2013-02-20 | 2017-02-21 | Novartis Ag | Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells |
| US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症 |
| WO2015105522A1 (en) | 2014-01-13 | 2015-07-16 | Forman Stephen J | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| AU2015317351B2 (en) | 2014-09-19 | 2020-07-02 | City Of Hope | Costimulatory chimeric antigen receptor T cells targeting IL3Ra2 |
-
2014
- 2014-03-14 WO PCT/US2014/028961 patent/WO2015105522A1/en not_active Ceased
- 2014-03-14 EP EP14877876.4A patent/EP3094653B1/en active Active
- 2014-03-14 EP EP19204610.0A patent/EP3626748A1/en active Pending
- 2014-03-14 JP JP2016546921A patent/JP6560235B2/ja active Active
- 2014-03-14 CN CN201480076612.7A patent/CN107074957B/zh active Active
- 2014-03-14 AU AU2014376328A patent/AU2014376328A1/en not_active Abandoned
- 2014-03-14 CN CN202110425805.0A patent/CN113307880B/zh active Active
- 2014-03-14 ES ES14877876T patent/ES2767423T3/es active Active
- 2014-03-14 US US15/111,384 patent/US20160333108A1/en not_active Abandoned
-
2018
- 2018-12-14 US US16/221,257 patent/US20200040096A1/en not_active Abandoned
-
2020
- 2020-06-29 AU AU2020204351A patent/AU2020204351A1/en not_active Abandoned
-
2021
- 2021-10-25 US US17/510,099 patent/US12522667B2/en active Active
-
2023
- 2023-05-17 AU AU2023203097A patent/AU2023203097A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507919A5 (enExample) | ||
| KR102898514B1 (ko) | 다양한 다중 항원의 표적화를 위한 역방향 범용 키메라 항원 수용체 발현 면역 세포, 이의 제조 방법 및 암, 감염증 및 자가면역 장애의 치료를 위한 이의 용도 | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| ES2767423T3 (es) | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso | |
| Zhukovsky et al. | Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection | |
| TWI773647B (zh) | 新穎pd-1免疫調控劑 | |
| Rahbarizadeh et al. | CAR T-cell bioengineering: single variable domain of heavy chain antibody targeted CARs | |
| JP2020530989A5 (enExample) | ||
| RU2017110279A (ru) | Комбинированная терапия на основе нацеленных на опухоль иммуноцитокинов, содержащих вариант il-2, и антител к человеческому pd-l1 | |
| CN118546960A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| JP2015527070A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| JP2019523630A5 (enExample) | ||
| RU2016138422A (ru) | Химерный антигенный рецептор | |
| CN114085855A (zh) | 通用嵌合抗原受体表达性免疫细胞及其制造方法和治疗用途 | |
| CN108367070B (zh) | 免疫毒素与检查点抑制剂的组合治疗 | |
| Satta et al. | Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors | |
| US20230134345A1 (en) | Chimeric antigen receptor comprising third signal receptor and use thereof | |
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| Kato et al. | Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies | |
| Chen et al. | Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies | |
| Tettamanti et al. | Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors | |
| Donda et al. | In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts | |
| JP7232547B2 (ja) | ＣＤＲ１領域に突然変異したヒト化ＣＤ１９ ｓｃＦｖを有するＣＡＲ－Ｔ細胞 | |
| US20180028632A1 (en) | Method of treating tumors with nk and nkt cells expressing anti-ssea4 chimeric antigen receptors |